New Study Confirms Bioavailability of FloraGlo Lutein

A new study underlines the superior bioavailability of FloraGlo lutein, combined with Actilease beadlet technology, to the eye’s macula. The study was performed by Kemin Health LC (Des Moines, IA), developer of FloraGlo, and DSM Nutritional Products (Parsippany, NJ), developer of Actilease.

The randomized, double-blind, two-phase, crossover study provided 48 healthy subjects with either 20 mg of unesterified lutein in an alginate matrix or FloraGlo lutein microencapsulated using Actilease. Using Actilease, FloraGlo is broken into microparticles that are housed in a water-soluble shell.

Macular pigment optical density (MPOD), which may be a biomarker for age-related macular degeneration, was measured. The study found that MPOD after the FloraGlo treatment was 0.45 µmol/L (a 169.7% increase from baseline), versus a lower 0.23 µmol/L MPOD level (a 34.5% increase from baseline) resulting from the alternative treatment.

The companies say this study supports FloraGlo’s efficacy and are using it as evidence to point out that “not all lutein sources are equally bioavailable.”